In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Neogenomics Inc (NASDAQ: NEO) closed at $11.8 up 0.77% from its previous closing price of $11.71. In other words, the price has increased by $0.77 from its previous closing price. On the day, 1.44 million shares were traded. NEO stock price reached its highest trading level at $11.9401 during the session, while it also had its lowest trading level at $11.625.
Ratios:
For a deeper understanding of Neogenomics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 25 ’25 when Olivo Alicia C sold 20,916 shares for $12.00 per share. The transaction valued at 250,992 led to the insider holds 31,083 shares of the business.
ALICIA OLIVO bought 11,939 shares of NEO for $138,612 on Nov 25 ’25. On Oct 16 ’25, another insider, ALICIA OLIVO, who serves as the Officer of the company, bought 4,918 shares for $9.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1526776064 and an Enterprise Value of 1785905792. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.15 while its Price-to-Book (P/B) ratio in mrq is 1.81. Its current Enterprise Value per Revenue stands at 2.518 whereas that against EBITDA is -518.706.
Stock Price History:
The Beta on a monthly basis for NEO is 1.57, which has changed by -0.3555311 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 13.87%, while the 200-Day Moving Average is calculated to be 38.28%.
Shares Statistics:
For the past three months, NEO has traded an average of 3.23M shares per day and 1687320 over the past ten days. A total of 128.89M shares are outstanding, with a floating share count of 123.05M. Insiders hold about 4.90% of the company’s shares, while institutions hold 97.04% stake in the company. Shares short for NEO as of 1763078400 were 8416654 with a Short Ratio of 2.61, compared to 1760486400 on 6508598. Therefore, it implies a Short% of Shares Outstanding of 8416654 and a Short% of Float of 8.959999999999999.
Earnings Estimates
The performance of Neogenomics Inc (NEO) in the stock market is under the watchful eye of 12.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.01, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.12 and $0.08 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.18, with 12.0 analysts recommending between $0.3 and $0.06.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $188.4M this quarter.It ranges from a high estimate of $193M to a low estimate of $186.6M. As of. The current estimate, Neogenomics Inc’s year-ago sales were $172MFor the next quarter, 13 analysts are estimating revenue of $187.98M. There is a high estimate of $194.32M for the next quarter, whereas the lowest estimate is $183M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $730.2M, while the lowest revenue estimate was $723.7M, resulting in an average revenue estimate of $725.56M. In the same quarter a year ago, actual revenue was $660.57MBased on 13 analysts’ estimates, the company’s revenue will be $797.81M in the next fiscal year. The high estimate is $807.13M and the low estimate is $784.8M.
